ArticleLeukemia2017
Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.
Abstract read
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Targeting lysosome-dependent cell death in cancer: towards therapeutic strategies.Biomarker research · 2026Review
- Cathepsin G is associated with cerebral vascular injury in myeloid leukemia: a pathologic insight into intracranial hemorrhage.Research and practice in thrombosis and haemostasis · 2026Article
- LTF promotes central nervous system leukemia progression via neutrophil serine proteases.Frontiers in pharmacology · 2026Article
- Article
- Exploring Renin-angiotensin System Genes as Novel Prognostic Biomarkers for Oral Squamous Cell Carcinoma.International journal of medical sciences · 2025Article
- The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour.International journal of molecular sciences · 2023Review
- CTSG Suppresses Colorectal Cancer Progression through Negative Regulation of Akt/mTOR/Bcl2 Signaling Pathway.International journal of biological sciences · 2023Article
- Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.Biomolecules · 2022Review
- Article
- 29th Annual GP2A Medicinal Chemistry Conference.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Role of lysosomes in physiological activities, diseases, and therapy.Journal of hematology & oncology · 2021Review
- Bioinformatics Analyses Indicate That Cathepsin G (CTSG) is a Potential Immune-Related Biomarker in Oral Squamous Cell Carcinoma (OSCC).OncoTargets and therapy · 2021Article
- Inflammasome Activation in Myeloid Malignancies-Friend or Foe?Frontiers in cell and developmental biology · 2021Review
- Article
- An improved clear cell renal cell carcinoma stage prediction model based on gene sets.BMC bioinformatics · 2020Article
- The Important Role of Perituberal Tissue in Epileptic Patients with Tuberous Sclerosis Complex by the Transcriptome Analysis.BioMed research international · 2020Article
- Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis.Cell stem cell · 2019Article
- Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.Oncotarget · 2018Article
- Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 1 country.
Gheath AlatrashStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Haven R Garber *Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Mao Zhang *Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Pariya SukhumalchandraStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Yihua QiuLeukemia, MD Anderson Cancer Center, Houston, TX.
Haroon JakherStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Alexander A PerakisStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Lisa BeckerStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Suk Young YooBioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX.
Karen C DwyerStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Kevin CoombesBiomedical Informatics, Ohio State University, Columbus, OH.
Amjad H TalukderMelanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX.
Lisa S St JohnStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Vladimir SenyukovPediatrics, MD Anderson Cancer Center, Houston, TX.
Dean A LeePediatrics, MD Anderson Cancer Center, Houston, TX.
Anna SergeevaStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Hong HeStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Qing MaStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Paul M ArmisteadLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
Jason RoszikMelanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX.
Elizabeth A MittendorfSurgical Oncology, MD Anderson Cancer Center, Houston, TX.
Jeffrey J MolldremStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
David HawkeSystems Biology, MD Anderson Cancer Center, Houston, TX.
Gregory LizeeMelanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX.
Steven M KornblauLeukemia, MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USThe Ohio State University · USUniversity of North Carolina at Chapel Hill · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7MLeukemia Specific Splice Isoforms as Neo-Antigens for T-Cell ImmunotherapyR01CA201225 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARMISTEAD, PAUL MICHAEL · 2016 to 2020
$2.3MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA201225
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCathepsin GGene ExpressionHeterograftsHumansImmunotherapyLeukemia, Myeloid, AcuteMiceCathepsin GCTSG protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.